> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Amgen Names Ex-Yum! Brands CEO David Gibbs To Its Board, With Audit And Pay Committee Seats
- URL: https://www.bullished.co/amgen-names-ex-yum-brands-ceo-david-gibbs-to-its-board-with-audit-and-pay-committee-seats-a30d999a/
- Published: 2026-10-27T10:25:55.000Z
- Updated: 2026-10-27T10:25:55.000Z
- Description: Gibbs, who also sits on the PepsiCo and Under Armour boards, takes his seat immediately, lifting Amgen's board to 13 directors.
- Author: Matteo Parrino
- Tags: SEC Filings, AMGN, Industry: Healthcare

Amgen put David W. Gibbs, the recently retired chief executive of Yum! Brands, on its board [effective immediately](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000144/amgn-20261026.htm?ref=bullished.co) on Monday, [according to an 8-K](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000144/amgn-20261026.htm?ref=bullished.co). He will serve on the Audit Committee and the Compensation and Management Development Committee.

## A restaurant chief joins a drugmaker's board

Gibbs was CEO of Yum! Brands, the parent of Taco Bell and Kentucky Fried Chicken, from 2020 to September 2025, and has advised the company since October 2025, the filing says. Amgen said that as CEO he led a digital transformation and widened the company's footprint to [nearly 61,000 locations](https://www.prnewswire.com/news-releases/amgen-appoints-david-w-gibbs-to-board-of-directors-302919950.html?ref=bullished.co).

He has been a director of Under Armour since 2021, where he chairs the Human Capital and Compensation Committee, and of PepsiCo since 2026, where he sits on the Audit Committee. He holds a bachelor's degree in mathematical science from Johns Hopkins University and an MBA from Duke University's Fuqua School of Business.

Amgen chairman and CEO Robert A. Bradway said Gibbs's "experience creating direct relationships with customers will help inform how we prepare for future launches and bring innovative treatments to more patients around the world."

Amgen discovers, develops, manufactures and delivers medicines for serious diseases. Its marketed products include Repatha, Otezla, ENBREL, Prolia, EVENITY, BLINCYTO, KYPROLIS and Vectibix.

## Board size and director pay

With Gibbs, the board has [13 directors, 12 of them independent](https://www.prnewswire.com/news-releases/amgen-appoints-david-w-gibbs-to-board-of-directors-302919950.html?ref=bullished.co). The filing reports no transactions between Gibbs or his immediate family and Amgen that would require disclosure.

He gets the standard non-employee director package: a pro-rated share of the $115,000 annual cash retainer and of the $12,500 committee meeting retainers, both through December 31, 2026.

His stock grant is 7/12 of the annual award of fully vested restricted stock units, which carries a grant-date fair value of $220,000\. It is due two business days after Amgen releases its third-quarter 2026 earnings.

Gibbs's restricted stock units arrive two business days after Amgen's third-quarter 2026 earnings release.

### Sources

- [8-K Filing — AMGEN INC (AMGN)](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000144/amgn-20261026.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit amgn-ex99\_1.htm — AMGEN INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000144/amgn-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS](https://www.prnewswire.com/news-releases/amgen-appoints-david-w-gibbs-to-board-of-directors-302919950.html?ref=bullished.co) — prnewswire.com